NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation
TORONTO and HAIFA, Israel, Feb. 14, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is excited to announce that it will be presenting at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting (“ISCT 2025”), a major global cell and
February 16, 2025